- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Generate Biomedicines, Inc. Common Stock(GENB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GENB
11/13/2026: GENB (1-star) is currently NOT-A-BUY. Pass it for now.
Generate Biomedicines is a clinical-stage biotechnology company that utilizes artificial intelligence and machine learning through its proprietary Generate Platform to design novel protein therapeutics. The company's primary strengths lie in its advanced computational platform, substantial cash reserves following its early 2026 initial public offering, and strategic partnerships with major pharmaceutical leaders. Its core growth story centers on advancing an internal pipeline of engineered candidates across oncology, immunology, and metabolic diseases. However, the company faces notable financial and execution risks, including ongoing net losses, an absence of approved commercial products, and the inherent clinical attrition rates of drug development. The stock is best suited for growth-oriented investors with high risk tolerance who are willing to monitor upcoming clinical readouts and partnership developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high-growth exposure to the burgeoning intersection of artificial intelligence and biotechnology drug development. |
| Momentum investor | Strong fit while signal remains positive | Trading momentum is heavily influenced by clinical milestone announcements, partnership updates, and broader biotech sentiment. |
| Value investor | Weak fit | The company lacks current earnings, positive cash flow, or traditional valuation metrics due to its clinical-stage status. |
| Dividend investor | Weak fit | As a clinical-stage biotechnology firm, all capital is retained to fund research and development rather than distributed as dividends. |
| Low-risk investor | Weak fit | High clinical trial uncertainties, lack of commercial products, and market volatility present significant risk profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech equities frequently experience sharp price swings driven by clinical trial readouts and market sentiment. |
| Valuation risk | Medium / high | Valuation relies heavily on future discounted cash flows from pipeline assets that carry high clinical failure rates. |
| Competition risk (AI drug discovery competition) | High | Rapid technological advances by peers and well-capitalized legacy pharma can disrupt market positioning. |
| Business quality | Medium | While the technological platform is sophisticated, the business model remains unproven commercially without approved drugs. |
| Dividend income | Low / none | The company pays no dividend and focuses entirely on capital appreciation and pipeline reinvestment. |
| Execution risk | High | Success depends entirely on successfully executing clinical trials and validating AI-designed protein targets in humans. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.56B USD | Price to earnings Ratio - | 1Y Target Price 27 |
Price to earnings Ratio - | 1Y Target Price 27 | ||
Volume (30-day avg) 979.2K shares | Beta - | 52 Weeks Range 11.00 - 22.67 | Updated Date 11/15/2026 |
52 Weeks Range 11.00 - 22.67 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.44 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -50.81% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing Agreements | Upfront payments, research funding, and clinical milestone fees from major pharmaceutical partnerships like Novartis and Zealand Pharma. | Revenue currently stems from validating the AI platform with partners rather than direct commercial drug sales. |
| Future Proprietary Therapeutics | Anticipated commercial sales and royalties from internally developed oncology, immunology, and metabolic pipeline assets. | Long-term value creation depends heavily on successfully bringing wholly-owned drugs to market. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.16B | Price to Sales(TTM) 73.96 |
Enterprise Value 1.16B | Price to Sales(TTM) 73.96 | ||
Enterprise Value to Revenue 43.88 | Enterprise Value to EBITDA - | Shares Outstanding 129.10M | Shares Floating 61.20M |
Shares Outstanding 129.10M | Shares Floating 61.20M | ||
Percent Insiders 14.12 | Percent Institutions 82.45 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

